These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20688355)

  • 41. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
    Coss A; Tosetto M; Fox EJ; Sapetto-Rebow B; Gorman S; Kennedy BN; Lloyd AT; Hyland JM; O'Donoghue DP; Sheahan K; Leahy DT; Mulcahy HE; O'Sullivan JN
    Cancer Lett; 2009 Apr; 276(2):228-38. PubMed ID: 19111388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
    Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parotid carcinoma: expression of kit protein and epidermal growth factor receptor.
    Sørensen KB; Godballe C; de Stricker K; Krogdahl A
    J Oral Pathol Med; 2006 May; 35(5):286-91. PubMed ID: 16630292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS; Fletcher JA
    Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
    Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
    Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
    Fritz P; Cabrera CM; Dippon J; Gerteis A; Simon W; Aulitzky WE; van der Kuip H
    Breast Cancer Res; 2005; 7(3):R374-84. PubMed ID: 15987433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oncocytic carcinoma of the breast: frequency, morphology and follow-up.
    Ragazzi M; de Biase D; Betts CM; Farnedi A; Ramadan SS; Tallini G; Reis-Filho JS; Eusebi V
    Hum Pathol; 2011 Feb; 42(2):166-75. PubMed ID: 21111455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases.
    Guan B; Wang H; Cao S; Rao Q; Wang Y; Zhu Y; Shi Q; Yin H; Wang X; Zhou X
    Ann Diagn Pathol; 2011 Aug; 15(4):225-32. PubMed ID: 21396871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin.
    da Cunha IW; De Brot L; Carvalho KC; Rocha RM; Fregnani JH; Falzoni R; Ferreira Fde O; Aguiar S; Lopes A; Muto NH; Reis LF; Soares FA; Vassallo J
    Ann Surg Oncol; 2012 Jun; 19(6):1790-9. PubMed ID: 22203181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
    Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas.
    Piris A; Scopsi L; Clemente C; Cetti Serbelloni F; Mihm MC; Hoang MP
    Am J Dermatopathol; 2010 Aug; 32(6):586-92. PubMed ID: 20534988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation.
    Gwin K; Lezon-Geyda K; Harris L; Tavassoli FA
    Int J Surg Pathol; 2011 Feb; 19(1):20-5. PubMed ID: 19411277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
    Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The value of expression of EGFR, telomerase and topoisomerase IIα in malignant effusion smears before and after chemotherapy.
    Koutsionasios J; Diab A; Athanasiadou AM; Petrakakou E; Marinos G; Kalyteraki J; Athanasiadou P; Konstantopoulos K
    J BUON; 2012; 17(3):554-9. PubMed ID: 23033298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.
    Macarenco RS; Uphoff TS; Gilmer HF; Jenkins RB; Thibodeau SN; Lewis JE; Molina JR; Yang P; Aubry MC
    Mod Pathol; 2008 Sep; 21(9):1168-75. PubMed ID: 18587327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.